cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.22926266
title: Supplementary Material for: Burden of acute kidney injury among adult hospital patients in the Italian Lombardy Region – a 20 years real world data analysis

description: Background: Acute kidney injury (AKI) is a frequent condition, with persisted shortage of large-scale epidemiological studies. We analyzed the population-wide healthcare system of the Italian Lombardy region over the 2000-2019 period, and evaluated AKI incidence, mortality, and related healthcare resources utilization and cost in all citizens 40 years and older. Methods: The retrospective cohort analysis of an administrative claims database that routinely collects information about health care provision in a high-income region with 10 million citizens. Over 20 years, AKI was identified in 84,384 hospital discharge records by the International Classification of Diseases 9th Revision codes (mean age 77.4±11.6 years, 52.5% were males). Results: From 2000 to 2019, the AKI rates per 100,000 population changed from 32.9 to 90.5 for incidence, from 4.7 to 11.9 for mortality, and from 32.3 to 44.1 for years of life lost (YLLs), respectively. In-hospital mortality changed slightly (14.2% and 13.2%, respectively), while 30-day mortality decreased from 21.5% to 17.4%, respectively. Incidence rates increased with age and were higher in males, and varied almost four-fold between provinces. The median hospitalization cost was €4,014 (IQR 3,652; 4,134), and the annual cost of treatment risen from €5.2 million in 2000 to €22.9 million in 2019. Hemodialysis was administered in 7.4% of hospitalizations. Over the total study period the cumulative AKI burden accounted for 11,420 in-hospital deaths, 63,370.8 YLLs, and €329 million of direct cost. Conclusions: This real-world analysis demonstrates the high burden of AKI with prominent geographical differences that require further implementation of preventive and diagnostic actions.
DOI: 10.6084/m9.figshare.22926266.v1
title: Supplementary Material for: Burden of acute kidney injury among adult hospital patients in the Italian Lombardy Region – a 20 years real world data analysis

description: Background: Acute kidney injury (AKI) is a frequent condition, with persisted shortage of large-scale epidemiological studies. We analyzed the population-wide healthcare system of the Italian Lombardy region over the 2000-2019 period, and evaluated AKI incidence, mortality, and related healthcare resources utilization and cost in all citizens 40 years and older. Methods: The retrospective cohort analysis of an administrative claims database that routinely collects information about health care provision in a high-income region with 10 million citizens. Over 20 years, AKI was identified in 84,384 hospital discharge records by the International Classification of Diseases 9th Revision codes (mean age 77.4±11.6 years, 52.5% were males). Results: From 2000 to 2019, the AKI rates per 100,000 population changed from 32.9 to 90.5 for incidence, from 4.7 to 11.9 for mortality, and from 32.3 to 44.1 for years of life lost (YLLs), respectively. In-hospital mortality changed slightly (14.2% and 13.2%, respectively), while 30-day mortality decreased from 21.5% to 17.4%, respectively. Incidence rates increased with age and were higher in males, and varied almost four-fold between provinces. The median hospitalization cost was €4,014 (IQR 3,652; 4,134), and the annual cost of treatment risen from €5.2 million in 2000 to €22.9 million in 2019. Hemodialysis was administered in 7.4% of hospitalizations. Over the total study period the cumulative AKI burden accounted for 11,420 in-hospital deaths, 63,370.8 YLLs, and €329 million of direct cost. Conclusions: This real-world analysis demonstrates the high burden of AKI with prominent geographical differences that require further implementation of preventive and diagnostic actions.
DOI: 10.5519/qd.uqt4garx
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (1 records)
DOI: 10.6084/m9.figshare.22926152
title: Accelerated Traction of Impacted Canines

description: These are the underlying files for the statistical analysis of the variables studied in this research project.
DOI: 10.21227/ytj1-hz59
title: The video of Cu-doped TiO2-x nanoscale memristor and  applications in coupled neurons

description:  A physical memristor is introduced into heterogeneous coupled neurons. Using the physical memristor, various complex firing patterns are observed. By analyzing the effects of electromagnetic induction on the firing patterns of the coupled neurons, multiple firing patterns are found, such as two coexisting chaotic firing patterns, transient chaos, and some other complex firing patterns. The memristive coupled neurons can better simulate the firing activity of the biological nervous system. In addition, phase synchronization of the coupled neurons is analyzed. Finally, a circuit is built with a physical memristor, which processes the manufacturing of memristors for adjustable, to explore the effect of the physical memristor on neuronal firing activities.
DOI: 10.6084/m9.figshare.22926488
title: Supplementary Material for: Burden of acute kidney injury among adult hospital patients in the Italian Lombardy Region – a 20 years real world data analysis

description: Background: Acute kidney injury (AKI) is a frequent condition, with persisted shortage of large-scale epidemiological studies. We analyzed the population-wide healthcare system of the Italian Lombardy region over the 2000-2019 period, and evaluated AKI incidence, mortality, and related healthcare resources utilization and cost in all citizens 40 years and older. Methods: The retrospective cohort analysis of an administrative claims database that routinely collects information about health care provision in a high-income region with 10 million citizens. Over 20 years, AKI was identified in 84,384 hospital discharge records by the International Classification of Diseases 9th Revision codes (mean age 77.4±11.6 years, 52.5% were males). Results: From 2000 to 2019, the AKI rates per 100,000 population changed from 32.9 to 90.5 for incidence, from 4.7 to 11.9 for mortality, and from 32.3 to 44.1 for years of life lost (YLLs), respectively. In-hospital mortality changed slightly (14.2% and 13.2%, respectively), while 30-day mortality decreased from 21.5% to 17.4%, respectively. Incidence rates increased with age and were higher in males, and varied almost four-fold between provinces. The median hospitalization cost was €4,014 (IQR 3,652; 4,134), and the annual cost of treatment risen from €5.2 million in 2000 to €22.9 million in 2019. Hemodialysis was administered in 7.4% of hospitalizations. Over the total study period the cumulative AKI burden accounted for 11,420 in-hospital deaths, 63,370.8 YLLs, and €329 million of direct cost. Conclusions: This real-world analysis demonstrates the high burden of AKI with prominent geographical differences that require further implementation of preventive and diagnostic actions.
DOI: 10.6084/m9.figshare.22926488.v1
title: Supplementary Material for: Burden of acute kidney injury among adult hospital patients in the Italian Lombardy Region – a 20 years real world data analysis

description: Background: Acute kidney injury (AKI) is a frequent condition, with persisted shortage of large-scale epidemiological studies. We analyzed the population-wide healthcare system of the Italian Lombardy region over the 2000-2019 period, and evaluated AKI incidence, mortality, and related healthcare resources utilization and cost in all citizens 40 years and older. Methods: The retrospective cohort analysis of an administrative claims database that routinely collects information about health care provision in a high-income region with 10 million citizens. Over 20 years, AKI was identified in 84,384 hospital discharge records by the International Classification of Diseases 9th Revision codes (mean age 77.4±11.6 years, 52.5% were males). Results: From 2000 to 2019, the AKI rates per 100,000 population changed from 32.9 to 90.5 for incidence, from 4.7 to 11.9 for mortality, and from 32.3 to 44.1 for years of life lost (YLLs), respectively. In-hospital mortality changed slightly (14.2% and 13.2%, respectively), while 30-day mortality decreased from 21.5% to 17.4%, respectively. Incidence rates increased with age and were higher in males, and varied almost four-fold between provinces. The median hospitalization cost was €4,014 (IQR 3,652; 4,134), and the annual cost of treatment risen from €5.2 million in 2000 to €22.9 million in 2019. Hemodialysis was administered in 7.4% of hospitalizations. Over the total study period the cumulative AKI burden accounted for 11,420 in-hospital deaths, 63,370.8 YLLs, and €329 million of direct cost. Conclusions: This real-world analysis demonstrates the high burden of AKI with prominent geographical differences that require further implementation of preventive and diagnostic actions.
DOI: 10.34740/kaggle/dsv/5715498
title: Global Genomic Neurofibromatosis Neoplasia
DOI: 10.5281/zenodo.4729725
title: D1.1.ALLINTERACT_RawData

description: This dataset contains the raw data obtained from social media interactions (Twitter, Facebook, Instagram and Reddit) among citizens about citizen participation in science and research with social impact related to two Sustainable Development Goals: Quality Education and Gender Equality. The data collection has followed a twofold strategy 1) Top-Down, in which researchers identified and selected relevant Twitter and Instagram hashtags and Facebook and Reddit pages and 2) Bottom-Up, in which Twitter hashtags were selected based on daily Trending Topics. The data was collected between March 9<sup>th</sup> and March 16<sup>th</sup> 2021 and has been obtained, cleaned and anonymized following ALLINTERACT Protocol for Social Media Analytics. This dataset is part of EC Horizon 2020 project ALLINTERACT Widening and diversifying citizen engagement in science (872396). We provide five Excel files (one for each social network explored). Each file contains the main information of the extracted messages, however the information extracted in each case is slightly different. <strong>Twitter</strong>: Row ID, Tweet ID, Tweet, Time, Tweet Type, Retweeted By, Number of Retweets, Hashtags, Number of Tweets , Number of Followers, Number Following <strong>Facebook</strong>: Row ID, Post ID, Post, Link, Link Name, Link Caption, Link Description, Video, Type, Likes, Created Time, Updated Time, Comment ID, Comment Text, Comment Likes, Comment Time, Page Likes <strong>Instagram</strong>: Url, content, likes, comments, date <strong>Reddit</strong>: Row ID, sub_id, sub_title, sub_text, sub_score, sub_date, sub_link, comment_id, comment_body, comment_score, comment_date, comment_link Funding: We acknowledge support of this work by the project <em>"ALLINTERACT Widening and diversifying citizen engagement in science</em>” (872396) from the European Commission Horizon 2020 programme.
description: {"references": ["Flecha, R., & Pulido, C. (2021). Allinteract - Social Media Analytics Protocol is licensed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License is available in https://archive.org/details/@crea_research"]}
DOI: 10.34740/kaggle/dsv/5715510
title: Egypt Gold Prices | Daily Updated
DOI: 10.6084/m9.figshare.22926705
title: Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

description: This study evaluated the clinical efficacy and safety of interleukin-1 (IL-1) blockade for patients with COVID-19. The PubMed, Web of Science, Ovid Medline, Embase and Cochrane Library databases were searched for relevant articles from their inception to 25 September 2022. Only randomized clinical trials (RCTs) that assessed the clinical efficacy and safety of IL-1 blockade in the treatment of patients with COVID-19 were included. This meta-analysis included seven RCTs. No significant difference in the all-cause mortality rate of patients with COVID-19 was observed between the IL-1 blockade and control groups (7.7 vs. 10.5%, odds ratio [OR] = 0.83, 95% confidence interval [CI] 0.57–1.22; <i>I</i><sup>2</sup> = 18%). However, the study group was at significantly lower risk of requiring mechanical ventilation (MV) compared with the control group (OR = 0.53, 95% CI 0.32–0.86; <i>I</i><sup>2</sup> = 24%). Finally, the risk of adverse events was similar between the two groups. IL-1 blockade does not provide increased survival benefits in hospitalized patients with COVID-19, but it may reduce the need for MV. Furthermore, it is a safe agent for use in the treatment of COVID-19.&gt; This systematic review and meta-analysis of randomized clinical trials (RCTs) evaluated the clinical efficacy and safety of interleukin-1 (IL-1) blockade for patients with COVID-19.Based on the analysis of six RCTs, no significant difference in the all-cause mortality rate of patients with COVID-19 was observed between the IL-1 blockade and control groups.The study group using IL1 was associated with a significantly lower risk of requiring mechanical ventilation compared with the control group.The risk of adverse events was similar between the study and the control groups. This systematic review and meta-analysis of randomized clinical trials (RCTs) evaluated the clinical efficacy and safety of interleukin-1 (IL-1) blockade for patients with COVID-19. Based on the analysis of six RCTs, no significant difference in the all-cause mortality rate of patients with COVID-19 was observed between the IL-1 blockade and control groups. The study group using IL1 was associated with a significantly lower risk of requiring mechanical ventilation compared with the control group. The risk of adverse events was similar between the study and the control groups.
DOI: 10.6084/m9.figshare.22926705.v1
title: Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

description: This study evaluated the clinical efficacy and safety of interleukin-1 (IL-1) blockade for patients with COVID-19. The PubMed, Web of Science, Ovid Medline, Embase and Cochrane Library databases were searched for relevant articles from their inception to 25 September 2022. Only randomized clinical trials (RCTs) that assessed the clinical efficacy and safety of IL-1 blockade in the treatment of patients with COVID-19 were included. This meta-analysis included seven RCTs. No significant difference in the all-cause mortality rate of patients with COVID-19 was observed between the IL-1 blockade and control groups (7.7 vs. 10.5%, odds ratio [OR] = 0.83, 95% confidence interval [CI] 0.57–1.22; <i>I</i><sup>2</sup> = 18%). However, the study group was at significantly lower risk of requiring mechanical ventilation (MV) compared with the control group (OR = 0.53, 95% CI 0.32–0.86; <i>I</i><sup>2</sup> = 24%). Finally, the risk of adverse events was similar between the two groups. IL-1 blockade does not provide increased survival benefits in hospitalized patients with COVID-19, but it may reduce the need for MV. Furthermore, it is a safe agent for use in the treatment of COVID-19.&gt; This systematic review and meta-analysis of randomized clinical trials (RCTs) evaluated the clinical efficacy and safety of interleukin-1 (IL-1) blockade for patients with COVID-19.Based on the analysis of six RCTs, no significant difference in the all-cause mortality rate of patients with COVID-19 was observed between the IL-1 blockade and control groups.The study group using IL1 was associated with a significantly lower risk of requiring mechanical ventilation compared with the control group.The risk of adverse events was similar between the study and the control groups. This systematic review and meta-analysis of randomized clinical trials (RCTs) evaluated the clinical efficacy and safety of interleukin-1 (IL-1) blockade for patients with COVID-19. Based on the analysis of six RCTs, no significant difference in the all-cause mortality rate of patients with COVID-19 was observed between the IL-1 blockade and control groups. The study group using IL1 was associated with a significantly lower risk of requiring mechanical ventilation compared with the control group. The risk of adverse events was similar between the study and the control groups.
DOI: 10.5281/zenodo.7948064
title: Testability prediction dataset: Design level

description: This dataset contains design metrics of the software projects in the SF110 corpus. The metrics have been extracted from the extended class diagram of these projects. The last column is the design testability value of each class in the dataset. The dataset is part of the paper entitled "<strong>Measuring and improving software testability at the design level</strong>".
DOI: 10.5281/zenodo.7948063
title: Testability prediction dataset: Design level

description: This dataset contains design metrics of the software projects in the SF110 corpus. The metrics have been extracted from the extended class diagram of these projects. The last column is the design testability value of each class in the dataset. The dataset is part of the paper entitled "<strong>Measuring and improving software testability at the design level</strong>".
DOI: 10.21227/8xbz-t363
title: Supplemental Materials for TPAMI3274826

description: This dataset contains source images of TPAMI3274826 (Fig. 10, Fig. 11, Fig. 13).
DOI: 10.5281/zenodo.6867878
title: Dataset from: Design and analysis of tweet-based election models for the 2021 Mexican legislative election

description: Processed data used for the analysis of the manuscript with title "Design and analysis of tweet-based election<br> models for the 2021 Mexican legislative election", by Vigna-Gómez et al.
DOI: 10.5281/zenodo.6867879
title: Dataset from: Design and analysis of tweet-based election models for the 2021 Mexican legislative election

description: Processed data used for the analysis of the manuscript with title "Design and analysis of tweet-based election<br> models for the 2021 Mexican legislative election", by Vigna-Gómez et al.
DOI: 10.5281/zenodo.7877001
title: Dataset from: Design and analysis of tweet-based election models for the 2021 Mexican legislative election

description: Processed data used for the analysis of the manuscript with title "Design and analysis of tweet-based election<br> models for the 2021 Mexican legislative election", by Vigna-Gómez et al.
DOI: 10.21227/m60v-jv38
title: source data

description: 我们的模拟使用Pycharm IDE，编译器版本是Python 3.8。我们的模拟在 Linux 5.10.0-8 通用系统上运行，使用第 11 代英特尔 （R） 酷睿 （TM） i7-11800H @ 2.30-GHz 处理器。仿真中使用的参数都是 Pypbc 库的标准参数
DOI: 10.5281/zenodo.7948157
title: Data from: Feeding and water temperature modulate the activity of gut microbiota in greater amberjack juveniles (Seriola dumerili)

description: Illumina (MiSeq v3) sequencing data for gut microbiota profiling in greater amberjack (<em>Seriola dumerili</em>) juveniles reared at three different water temperatures and sampled along a day cycle.
DOI: 10.5281/zenodo.7948156
title: Data from: Feeding and water temperature modulate the activity of gut microbiota in greater amberjack juveniles (Seriola dumerili)

description: Illumina (MiSeq v3) sequencing data for gut microbiota profiling in greater amberjack (<em>Seriola dumerili</em>) juveniles reared at three different water temperatures and sampled along a day cycle.
DOI: 10.34740/kaggle/dsv/5715796
title: 2021 World Population (updated daily)
DOI: 10.5281/zenodo.7948200
title: Coping and quality of life differences between emergency and rehabilitation healthcare workers.

description: Dataset
DOI: 10.5281/zenodo.7948199
title: Coping and quality of life differences between emergency and rehabilitation healthcare workers.

description: Dataset
DOI: 10.25934/pr00008928
title: Data Challenge - Phenotypic and Genomic Evolution of Antimicrobial Resistance among WHO Priority pathogens in LMICS

description: Multidrug resistance among bacterial pathogens is a global health threat. A disproportionate burden of this is borne by low and middle-income countries (LMICS). A recent review showed that in 2019 an estimated 4.9 million deaths were associated with bacterial antimicrobial resistance (AMR) while about 1.27 million deaths were attributable to bacterial AMR. Most mortality occurred in sub-Saharan Africa, especially the West African region. Unfortunately, infrastructure for surveillance is lacking in these settings resulting in a paucity of data on the estimation of the burden and evidence base to guide intervention. The six leading pathogens responsible for death attributable to bacteria AMR were Escherichia coli, Staphylococcus aureus, Klebsiella pneumonia, Streptococcus pneumonia, Acinetobacter baumannii and Pseudomonas aeruginosa. These bacterial pathogens are on the WHO priority pathogen list, a list of multidrug-resistant bacterial pathogens that pose the greatest threat to health and for which limited treatment options exist, they have been prioritized for new drug development. This review will utilize secondary data to provide insights into the magnitude of resistance among the WHO priority pathogen list of organisms and their phenotypic and genotypic evolution over time in LMICs. Their pattern of evolution and spread, including potential factors influencing these will be explored. The review will thus provide information to guide policy regarding AMR interventions in LMICs, guidance approaches to strengthening stewardship and help improve patient outcomes. The findings from this review will also identify critical gaps in research and policy efforts to reduce the burden of AMR in LMICs thereby informing public health practice, interventions and strengthening of health systems. As AMR does not respect boundaries, control of AMR in LMICS will potentially impact global transmission and burden reduction.
DOI: 10.6084/m9.figshare.22927685
title: <strong>AhmetDoganKuday.sav</strong>

description: Ahmet Doğan Kuday
DOI: 10.6084/m9.figshare.22927685.v1
title: <strong>AhmetDoganKuday.sav</strong>

description: Ahmet Doğan Kuday